India, July 29 -- Sandoz Group AG (SDZNY) a company focused on affordable medicine, announced that Brazil's health regulator ANVISA has granted marketing authorization for Owozy (semaglutide), a new treatment option for type-2 diabetes. The approval paves the way for launch in the second half of 2026.
Owozy, developed by Adalvo and is commercialized in Brazil by Sandoz, will be available in a pre-filled multi-dose disposable pen designed to simplify administration for patients and healthcare professionals. It is among the first new semaglutide therapies approved in Brazil, a market estimated at USD 1.8 billion.
Richard Sayno, CEO of Sandoz, said: "This first wave regulatory approval for a new semaglutide treatment option in Brazil marks m...